Gsa Capital Partners LLP Prelude Therapeutics Inc Transaction History

Gsa Capital Partners LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	SELL	$2.74 - $4.79 $6,167 - $10,782	-2,251 Reduced 3.09%	70,583 $218,000
Q2 2023 Aug 14, 2023	BUY	$4.45 - $8.12 $112,229 - $204,786	25,220 Added 52.97%	72,834 $327,000
Q1 2023 May 12, 2023	SELL	$4.58 - $7.34 $856 - $1,372	-187 Reduced 0.39%	47,614 $271,000
Q4 2022 Feb 13, 2023	SELL	$4.61 - $8.5 $29,374 - $54,162	-6,372 Reduced 11.76%	47,801 $289,000
Q3 2022 Nov 14, 2022	BUY	$5.0 - $8.82 $87,735 - $154,764	17,547 Added 47.91%	54,173 $358,000
Q2 2022 Aug 09, 2022	BUY	$4.0 - $7.55 $53,700 - $101,358	13,425 Added 57.86%	36,626 $191,000
Q1 2022 May 11, 2022	BUY	$6.9 - $13.22 $160,086 - $306,717	23,201 New	23,201 $160,000

33.9M

400

100

Ticker PRLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,369,200
Market Cap $75.3M
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.